fig5

Figure 5. The novel FAK inhibitor 10k enhances the activity of Osimertinib in vivo. (A) Tumor-bearing mice with H1975 (left panel) or H1975OR (right panel) xenografts were treated with 10k (20 mg/kg), Osimertinib (3 mg/kg), or a combination of both drugs at the same doses for 2 weeks. After one additional week, tumors were excised from the mice and photographed. Scale bars: 1 cm; (B) Tumor volumes were measured at regular intervals during the treatment. Statistical significance: P-values was set as follows: ^***P < 0.001. The graphs were created with GraphPad Prism. FAK: Focal adhesion kinase; H1975OR: H1975 Osimertinib resistant; Afa: Afatinib; Osi: Osimertinib.